Aurinia Pharmaceuticals
AUPH
11 hedge funds and large institutions have $30.7M invested in Aurinia Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
59% more capital invested
Capital invested by funds: $19.3M → $30.7M (+$11.4M)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.81M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$40.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.16K |
| 4 |
Citigroup
New York
|
+$609 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
-$59.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7.43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $9.27M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $9.01M | +$8.81M | +2,474,076 | New |
|
|
GPP
3
Great Point Partners
Greenwich,
Connecticut
| $8.88M | +$40.9K | +11,500 | +0.5% |
|
|
BBA
4
Baker Bros. Advisors
New York
| $2.6M | – | – | – |
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $485K | – | – | – |
|
|
CCMU
6
Cheyne Capital Management (UK)
London,
United Kingdom
| $323K | -$59.8K | -16,805 | -16% |
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| $46K | – | – | – |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $41K | -$7.43K | -2,086 | -16% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $11K | +$5.16K | +1,448 | +91% |
|
|
10
Citigroup
New York
| $1K | +$609 | +171 | New |
|
AUPH Hedge Fund Activity: Q4 2014 in Review
11 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2014, worth a combined $30.7M — up 59% from $19.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AUPH positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $8.81M. The largest seller was Cheyne Capital Management (UK), cutting an estimated $59.8K.
- 11 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $30.7M of Aurinia Pharmaceuticals stock for Q4 2014, up 59% quarter-over-quarter.
- 2 funds opened new Aurinia Pharmaceuticals positions in Q4 2014 and 0 closed out, a net change of +2 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2014 was RA Capital Management, an estimated $8.81M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2014 was Cheyne Capital Management (UK), an estimated $59.8K sold.
Based on aggregated 13F filings for Q4 2014.